Pregnancy associated hypertension associated with an increased frequency of subsequent hypertension and metabolic syndrome

February 01, 2015

In a study to be presented on Feb. 5 in an oral concurrent session at 2:45 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting™, in San Diego, researchers of the MFMU Network will present findings of long term cardiovascular and metabolic abnormalities five to ten years later in women with preeclampsia/gestational hypertension during pregnancy.

The study, titled Adverse Pregnancy Outcomes and Subsequent Metabolic Syndrome analyzed 825 women who were followed up approximately seven years after their delivery. At the time of enrollment in the original study, the women were pregnant and had mild gestational diabetes or lesser degrees of abnormal glucose values, but did not have a prior history of gestational diabetes mellitus or diabetes, chronic hypertension or renal or cardiovascular disease. At follow-up, women had anthropometric and blood pressure measurements, provided blood for laboratory measurements and were asked about medications and diet. A majority of the women were noted to have high waist circumference and low HDL-C at follow up.

The research concluded that in an obstetric population with no preexisting conditions, and no or only mild GDM in the index pregnancy, pregnancy associated hypertension, particularly when delivery occurred preterm, was associated with a higher frequency of subsequent hypertension and metabolic syndrome in the mother five to ten years later.

"This study provides additional support of the concept of pregnancy as a window to future health and the need for physicians to continue to monitor and counsel patients with conditions such as preeclampsia and gestational hypertension, especially if its onset was early or if the woman also delivered preterm," stated Madeline Rice, Ph.D., of the Milken Institute School of Public Health at the George Washington University, on behalf of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network in Bethesda, Md.
-end-
Abstract 33: Adverse Pregnancy Outcomes and Subsequent Metabolic Syndrome

Author: Madeline Rice1 1for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, Bethesda, MD

Objective: To evaluate whether preeclampsia/gestational hypertension (PE/GHTN) and preterm birth (PTB) are associated with maternal metabolic syndrome (MetSyn) later in life.

Study Design: Women enrolled in a mild gestational diabetes mellitus (GDM) treatment trial (abnormal oral glucose tolerance test (OGTT); fasting glucose <95 mg>88 cm), high triglycerides (?150 mg/dL), low high density lipoprotein cholesterol (HDL-C) (<50 mg>

Results: This analysis included 824 women (46% of eligible women from the original studies) who were followed up 7±1 years after the index pregnancy and were not pregnant at the time of follow-up. Mean age at follow-up was 36±6 years. Overall, 29% had MetSyn (33% in those with GDM and 24% in those without GDM; p=.005). High waist circumference and low HDL-C was observed in the majority of women. The frequency of MetSyn, and its components, was highest in the women who were delivered preterm and had PE/GHTN. After adjusting for confounding factors, PE/GHTN with or without PTB was significantly associated with subsequent hypertension and PE/GHTN with PTB was significantly associated with subsequent MetSyn.

Conclusion: In an obstetric population with no preexisting conditions, and no or only mild GDM in the index pregnancy, PE/GHTN, particularly when delivery occurred preterm, was associated with a higher frequency of long term cardiovascular and metabolic abnormalities in the mother 5-10 years later.

Society for Maternal-Fetal Medicine

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.